Education
About Us
Working with TipRanks
Follow Us
Acrux Limited (ARUXF)
OTHER OTC:ARUXF
ARUXF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume500.00
Average Volume (3M)33.00
Market Cap
$5.99M
Enterprise Value$20.76M
Total Cash (Recent Filing)AU$19.04M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 22, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 18, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding407,315,200
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.25
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Acrux Limited News
PremiumCompany Announcements
Acrux Limited Announces Registry Office Relocation
PremiumCompany Announcements
Acrux Limited Announces Director’s Acquisition of Options
PremiumCompany Announcements
Acrux Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Acrux Secures $1.73 Million Advance on R&D Tax Incentive
PremiumCompany Announcements
Acrux Limited Issues New Director Placement Shares
PremiumCompany Announcements
Acrux Limited Announces Quotation of New Securities on ASXPremiumCompany Announcements
Acrux Limited Highlights Future Prospects in Topical Pharmaceuticals
PremiumCompany Announcements
Acrux Limited Announces Investor Webinar to Discuss Half-Year Results---
Options Prices
Currently, No data available
---
Ownership Overview
ARUXF FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest stock price was $0.02 and its highest was $0.08 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is $5.99M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 22, 2025 which is in 118 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 25, 2025. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Notavailable dividend of $0.038 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 407,315,200 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in ARUXF
---
Acrux Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ARUXF Sentiment 71%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $96.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-132.58%
Trailing 12-Months
Asset Growth
-41.17%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
---
Technical Analysis
CSL
―
Nanosonics Limited
―
Immutep Ltd
―
Starpharma Holdings Limited
―
Race Oncology Ltd.
―
---